Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) with a Neutral.
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of...
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $...
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $...
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $...
